CDK4/6 Inhibitors Overcome Endocrine ESR1 Mutation-Related Resistance in Metastatic Breast Cancer Patients

CDK4/6 Inhibitors Overcome Endocrine ESR1 Mutation-Related Resistance in Metastatic Breast Cancer Patients

ESR1 mutations contribute to endocrine resistance and occur in a high percentage of hormone-receptor-positive (HR+) metastatic breast cancer (mBC) cases. Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) changed the treatment landscape of HR+ mBC, as they are able to overcome estrogen resistance. The...

Full description

Bibliographic Details
Main Authors: Stefania Crucitta, Martina Ruglioni, Giulia Lorenzini, Irene Bargagna, Giovanna Irene Luculli, Irene Albanese, Diana Bilancio, Francesca Patanè, Andrea Fontana, Romano Danesi, Marzia Del Re
Format: Article
Language:English
Published: MDPI AG 2023-02-01
Series:Cancers
Subjects:
ESR1 mutation
liquid biopsy
ctDNA
metastatic breast cancer
CDK4/6 inhibitor
Online Access:https://www.mdpi.com/2072-6694/15/4/1306

Similar Items

Similar Items